Literature DB >> 17357373

Effect of H1 antihistamines upon the cardiovascular system.

I Dávila1, J Sastre, J Bartra, A del Cuvillo, I Jáuregui, J Montoro, J Mullol, A L Valero.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17357373

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN： 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  5 in total

1.  No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

Authors:  Ester Donado; Iñaki Izquierdo; Iñaki Pérez; Olga García; Rosa M Antonijoan; Ignaci Gich; Anna Solans; Juana Peña; Joel Morganroth; Manuel J Barbanoj
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

Review 2.  Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects.

Authors:  Soja Shamizadeh; Knut Brockow; Johannes Ring
Journal:  Allergo J Int       Date:  2014-05-09

3.  Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.

Authors:  Anne-Françoise Schlit; Annie Delaunois; Aurore Colomar; Branderley Claudio; Luca Cariolato; Rossen Boev; Jean-Pierre Valentin; Christopher Peters; Victor S Sloan; Jürgen W G Bentz
Journal:  Pharmacol Res Perspect       Date:  2017-04-21

Review 4.  Cardiovascular safety of antihistamines.

Authors:  Anna Olasińska-Wiśniewska; Jerzy Olasiński; Stefan Grajek
Journal:  Postepy Dermatol Alergol       Date:  2014-06-13       Impact factor: 1.837

5.  Curcumin derivative, 2,6-bis(2-fluorobenzylidene)cyclohexanone (MS65) inhibits interleukin-6 production through suppression of NF-κB and MAPK pathways in histamine-induced human keratinocytes cell (HaCaT).

Authors:  Nurul Atika Razali; Nur Amiza Nazarudin; Kok Song Lai; Faridah Abas; Syahida Ahmad
Journal:  BMC Complement Altern Med       Date:  2018-07-16       Impact factor: 3.659
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.